Pharma Dividend Darlings: JNJ and MRK Lead the Pack

Two pharmaceutical companies, Johnson & Johnson and Merck, have shown impressive track records in delivering dividend growth to their shareholders. Johnson & Johnson has a remarkable streak of increasing its payouts for 64 consecutive years.

The company's diversified product lineup across pharmaceuticals and medical devices has helped it weather challenges such as patent cliffs and government drug price negotiations.

Johnson & Johnson's recent financial results were strong, with second-quarter sales coming in at $25.3 billion, up 6.6% year over year, while adjusted earnings per share climbed 4.7% year over year to $2.90.

Merck is also expected to perform well long-term despite facing challenges such as the patent cliff for its biggest growth driver, Keytruda.